Dados do Resumo

Título

CELL MEMBRANE-FUNCTIONALIZED NANOPARTICLES CONTAINING IMATINIB FOR CHRONIC MYELOID LEUKEMIA THERAPY

Introdução

Among the therapeutic alternatives to treat Chronic Myeloid Leukemia (CML), the Imatinib drug stands out, preventing the action of the oncoprotein, but also presenting side effects and primary resistance. In this aspect, the use of membrane-coated nanoparticles (NPS) allows for a more localized delivery with camouflage from the immune system, thus reducing both side effects and the chance of resistance to the therapy.

Objetivo

Our research aimed at treating K562 cell lines (CML) with Imatinib encapsulated by PLGA NPS, coated with K562 cell membranes, to improve CML therapy.

Métodos

The Imatinib- loaded nanoparticles (NPI) were synthesized by the nanoemulsion followed by washing in Amicon tubes. Membrane extraction was performed by washing the cells with PBS and gradient buffer, lysis with hypotonic buffer and ultracentrifugation. The NPS coating was performed by sonication in an ultrasonic bath of a solution containing NPI and cell membranes. Cell viability assays were carried out using the Resazurin fluorimetric method.

Resultados

The white NPS presented a size of 186.7 nm, Zeta potential (ZP) of -24.53 mV and stability of 7 weeks, while for the NPI they exhibited an average size of 171.41 nm, ZP of -20.39 mV, drug encapsulation efficiency of 96.5% and stability for 10 weeks. The NPI coated with the cell membrane (NPIMB) exhibited a PDI of 0.195, a size of 160.1 nm, and a charge of -18.99 mV. Cell viability assays indicated that free Imatinib showed greater cytotoxicity when compared to the nanoformulations, signaling a more contained delivery of the chemotherapy drug.

Conclusões

Therefore, NPIMB are therapeutic models that can promote a controlled release of drugs, with a potential reduction in side effects for the patient.

Financiador do resumo

The project was funded by the São Paulo Research Foundation (FAPESP). Identification number 2023/05402-1.

Palavras Chave

Chronic Myeloid Leukemia; Nanoparticles